ERCC1 and ovarian cancer: We have already demonstrated that a) additional detection of ERCC1-transcripts extented clinical value of CTCs from a prognostic biomarker to an independent predictor of platinum-resistance at primary diagnosis of ovarian cancer and b) ERCC1+CTCs may constitute a distinct subgroup of CTCs with a potentially platinum-resistant phenotype [21].